Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

ADR reporting: specifics needed

By News team

Brand names and batch numbers should be provided when reporting suspected adverse drug reactions to biological medicines, the Medicines and Healthcare products Regulatory Agency has advised in its latest issue of Drug Safety Update.

It reminds health professionals that biosimilar products with the same international non-proprietary name are not necessarily identical and that ADRs may be batch-specific.

Citation: The Pharmaceutical Journal URI: 11112556

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.